fibroblast growth factor receptor 2
| UniProt | Protein Name |
|---|---|
| P21802 |
|
| D2CGD1 |
|
| S4R381 |
|
| A0A141AXF1 |
|
| GO Term | Evidence Code | PMID |
|---|---|---|
| apoptotic process | ||
| epidermal growth factor receptor signaling pathway | ||
| cell-cell signaling | ||
| axonogenesis | ||
| positive regulation of cell population proliferation |
| GO Term | Evidence Code | PMID |
|---|---|---|
| extracellular region | ||
| nucleus | ||
| cytoplasm | ||
| Golgi apparatus | ||
| plasma membrane |
| GO Term | Evidence Code | PMID |
|---|---|---|
| protein tyrosine kinase activity | ||
| GPI-linked ephrin receptor activity | ||
| transmembrane-ephrin receptor activity | ||
| epidermal growth factor receptor activity | ||
| fibroblast growth factor receptor activity |
| DO ID | Disease Name | Source |
|---|---|---|
| DOID:0050331 | lacrimoauriculodentodigital syndrome 1 | |
| DOID:0050660 | Beare-Stevenson cutis gyrata syndrome | |
| DOID:0050861 | colorectal adenocarcinoma | |
| DOID:0060992 | bent bone dysplasia syndrome 1 | |
| DOID:0081289 | Antley-Bixler syndrome | |
| DOID:0081290 | Antley-Bixler syndrome without disordered steroidogenesis | |
| DOID:0111337 | Jackson-Weiss syndrome | |
| DOID:10534 | stomach cancer | |
| DOID:11054 | urinary bladder cancer | |
| DOID:12960 | acrocephalosyndactylia |
| Species | Gene ID | Alliance of Genome Resources | Orthologous MAtrix |
|---|---|---|---|
| 105554550 | MANLE04656 | ||
| 105577985 | CERAT13319 | ||
| 105717989 | AOTNA24567 | ||
| 105808669 | PROCO14789 | ||
| 105870804 | MICMU11821 | ||
| 105989771 | DIPOR13065 | ||
| 106576891 | SALSA57198 | ||
| 106846935 | EQUAS12112 | ||
| 107597642 | SINGR24775 | ||
| 108263349 | ICTPU27293 |
GlyCosmos is a member of the GlySpace Alliance together with GlyGen and Glycomics@ExPASy.
Supported by JST NBDC Grant Number JPMJND2204
Partly supported by NIH Common Fund Grant #1U01GM125267-01
This work is licensed under Creative Commons Attribution 4.0 International
GlyCosmos Portal v4.4.0
Last updated: December 8, 2025